Ascentage Pharma - מכפיל שווי פעילות להכנסות AAPG

Can the demand for resistant tumor therapies drive growth for Ascentage Pharma Group (AAPG)? Success depends on Olverembatinib sales, regulatory approvals, and liquidity. Business stability relies on late-stage developments in the US and China. A business valuation via EV/Sales visualizes the asset's dynamics, where the value 12973.75 captures the metric level.
Ascentage Pharma Group International - פילוחים אנליטיים ומדדי מפתח (AAPG)

An analysis of the EV-to-total-revenue multiple confirms the status of Ascentage Pharma Group (AAPG) as a non-cyclical oncology drug developer whose valuation is independent of seasonality. This indicator compares the total enterprise value of the business with annual turnover, excluding net debt, allowing investors to assess the real price of assets amid tight Fed policy and high market sensitivity to interest rates.